ERBB2 and breast cancer: Trastuzumab is a humanized monoclonal antibody that interferes with human epidermal growth factor receptor 2 (HER2), a member of the epidermal growth factor receptor family involved in modulation of cell proliferation and survival, which is overexpressed in 25–30% of all breast cancers (21).